Alto Neuroscience Secures $120M Private Placement to Fund Phase 3 ALTO-207 Trial

summarizeSummary

Alto Neuroscience announced a $120 million private placement of common stock and pre-funded warrants to fund the Phase 3 clinical trial of ALTO-207 in treatment-resistant depression and for general corporate purposes.

check_boxKey Events

• Private Placement Financing Secured

  Alto Neuroscience secured approximately $120 million in gross proceeds through a private placement of common stock and pre-funded warrants with institutional investors.

• Dilutive Offering Structure

  The company sold 2,900,000 shares of common stock at $20.00 per share and pre-funded warrants to purchase 3,100,000 shares at $19.9999 per warrant. The offering price represents a 14.5% discount to the current stock price of $23.40.

• Funding for Key Clinical Program

  Proceeds are primarily allocated to fund the development of ALTO-207 through a planned Phase 3 clinical trial in treatment-resistant depression, extending the company's capital runway through potential NDA submission.

• Board Expansion

  The Board of Directors will be expanded to seven members, effective March 16, 2026.

auto_awesomeAnalysis

This significant capital raise provides Alto Neuroscience with crucial funding to advance its lead candidate, ALTO-207, through a planned Phase 3 clinical trial and towards a potential NDA submission. For a life sciences company, securing financing for late-stage clinical development is a critical de-risking event, especially given the company's reported net loss of $63.2 million in fiscal year 2025. While the offering is highly dilutive, representing approximately 17.35% of the current market capitalization, and priced at a discount to the current stock price, the participation of institutional investors signals confidence in the company's precision neuroscience strategy and pipeline. The proceeds are expected to extend the company's cash runway significantly, enabling the completion of a key clinical milestone.